Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

CompletedOBSERVATIONAL
Enrollment

3,294

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions
Hepatitis C
Interventions
DRUG

Harvoni

Harvoni (90/400 mg) FDC tablet administered orally once daily

Trial Locations (125)

Unknown

Ageo-shi

Akita

Amagasaki-shi

Aomori

Arao-shi

Asahi-shi

Asahikawa-shi

Asakura-shi

Bunkyō City

Chiba

Chichibu-shi

Chuo-shi

Fujioka-shi

Fukui-shi

Fukuoka

Gifu

Hakodate-shi

Hamamatsu

Handa-shi

Hashima-shi

Hatsukaichi-shi

Higashiibaraki-gun

Hirosaki-shi

Hiroshima

Hitachi-shi

Hukui-shi

Ichikawa-shi

Iizuka-shi

Ikeda-shi

Inashiki-gun

Inzai-shi

Iruma-gun

Ise-shi

Iwaki

Izumo-shi

Izunokuni-shi

Kagoshima

Kamogawa-shi

Kanazawa

Karatsu-shi

Kashihara-shi

Kashiwa-shi

Kasukabe-shi

Kawagoe-shi

Kawaguchi-shi

Kawasaki-shi

Kirishima-shi

Kitakyushu-shi

Kitamoto-shi

Kobe

Kodaira-shi

Kofu

Komae-shi

Komaki-shi

Koriyama-shi

Koshigaya-shi

Kōtoku

Kuga-gun

Kuki-shi

Kumamoto

Kurashiki-shi

Kure-shi

Kurume-shi

Kyoto

Maebashi

Matsumoto-shi

Matsuyama

Minatoku

Miyazaki

Moriguchi-shi

Morioka

Nagakute-shi

Nagasaki

Nagoya

Nakagami-gun

Nerima-ku

Niigata

Nishinomiya-shi

Noshiro

Obihiro-shi

Ofukeshi

Okayama

Osaka

Osakasayama-shi

Oume-shi

Ōita

Ōmihachiman

Ōta-ku

Ōtsu

Saga

Saitama-shi

Sakaishi

Sano-shi

Sapporo

Sasebo-Shi

Sendai

Shimonoseki-shi

Shimotsuga-gun

Shimotsuke-shi

Shinagawa-ku

Shinjuku-ku

Shirakawa-shi

Shizuoka

Shunan-shi

Sumida-ku

Tagawa-shi

Takamatsu

Takasaki-shi

Toda-shi

Tokorozawa-shi

Tokushima

Tonami-shi

Toyama

Toyoake-shi

Ureshino-shi

Utsunomiya

Wakayama

Yachiyo-shi

Yamagata

Yanagawa-shi

Yatsushiro-shi

Yokkaichi-shi

Yokohama

Yonago-shi

Yoshida-gun

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY